Cargando…

The Amyloid-β Pathway in Alzheimer’s Disease

Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the center of Alzheimer’s disease (AD) pathophysiology. While the detailed molecular mechanisms of the pathway and the spatial-temporal dynamics leading to synaptic failure, neurodegeneration, and clinical onset are st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hampel, Harald, Hardy, John, Blennow, Kaj, Chen, Christopher, Perry, George, Kim, Seung Hyun, Villemagne, Victor L., Aisen, Paul, Vendruscolo, Michele, Iwatsubo, Takeshi, Masters, Colin L., Cho, Min, Lannfelt, Lars, Cummings, Jeffrey L., Vergallo, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758495/ https://www.ncbi.nlm.nih.gov/pubmed/34456336 http://dx.doi.org/10.1038/s41380-021-01249-0

Ejemplares similares

The amyloid-β pathway in Alzheimer's disease: a plain language summary
por: Hampel, Harald, et al.
Publicado: (2023)

State‐of‐the‐art of lumbar puncture and its place in the journey of patients with Alzheimer's disease
por: Hampel, Harald, et al.
Publicado: (2021)

CSF tau and β-amyloid as biomarkers for mild cognitive impairment
por: Hampel, Harald, et al.
Publicado: (2004)

β-Secretase1 biological markers for Alzheimer’s disease: state-of-art of validation and qualification
por: Hampel, Harald, et al.
Publicado: (2020)

A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease
por: Ashton, Nicholas J., et al.
Publicado: (2019)

Aptamarker prediction of brain amyloid-β status in cognitively normal individuals at risk for Alzheimer’s disease
por: Penner, Gregory, et al.
Publicado: (2021)

Amyloid-ß-directed immunotherapy for Alzheimer's disease
por: Lannfelt, L, et al.
Publicado: (2014)

High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer’s disease
por: Degerman Gunnarsson, Malin, et al.
Publicado: (2016)

Evaluation of major national dementia policies and health‐care system preparedness for early medical action and implementation
por: Hampel, Harald, et al.
Publicado: (2022)

Validation of a priori candidate Alzheimer’s disease SNPs with brain amyloid-beta deposition
por: Vacher, Michael, et al.
Publicado: (2019)

Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease
por: Amadoru, Sanka, et al.
Publicado: (2020)

Biomarkers for Alzheimer’s Disease (AD) and the Application of Precision Medicine
por: Lukiw, Walter J., et al.
Publicado: (2020)

Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals
por: Fandos, Noelia, et al.
Publicado: (2017)

Collagenous Alzheimer amyloid plaque component impacts on the compaction of amyloid-β plaques
por: Hashimoto, Tadafumi, et al.
Publicado: (2020)

Amyloid-Related Memory Decline in Preclinical Alzheimer’s Disease Is Dependent on APOE ε4 and Is Detectable over 18-Months
por: Thai, Christine, et al.
Publicado: (2015)

Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease
por: Jiang, Hong, et al.
Publicado: (2011)

Association of naturally occurring antibodies to β-amyloid with cognitive decline and cerebral amyloidosis in Alzheimer’s disease
por: Liu, Yu-Hui, et al.
Publicado: (2021)

The Sars-Cov-2 Pandemic and the Brave New Digital World of Environmental Enrichment to Prevent Brain Aging and Cognitive Decline
por: Hampel, Harald, et al.
Publicado: (2020)

Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer’s Precision Medicine and Pharmacology
por: Hampel, Harald, et al.
Publicado: (2019)

Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease
por: Portelius, Erik, et al.
Publicado: (2010)

Imago Mundi, Imago AD, Imago ADNI
por: Villemagne, Victor L, et al.
Publicado: (2014)

Relationship between amyloid and tau levels and its impact on tau spreading
por: Doré, Vincent, et al.
Publicado: (2021)

Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease
por: Sehlin, Dag, et al.
Publicado: (2016)

Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease
por: Dhiman, Kunal, et al.
Publicado: (2020)

Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease
por: Kerbler, Georg M, et al.
Publicado: (2014)

microRNA-Based Biomarkers in Alzheimer’s Disease (AD)
por: Zhao, Yuhai, et al.
Publicado: (2020)

Total Aβ(42)/Aβ(40) ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis
por: Doecke, James D., et al.
Publicado: (2020)

Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease
por: Voevodskaya, Olga, et al.
Publicado: (2016)

Mesial temporal tau in amyloid-β-negative cognitively normal older persons
por: Krishnadas, Natasha, et al.
Publicado: (2022)

Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score
por: Lim, Yen Ying, et al.
Publicado: (2015)

β-amyloid in biological samples: not all Aβ detection methods are created equal
por: Adlard, Paul A., et al.
Publicado: (2014)

(18)F-Florbetaben PET beta-amyloid binding expressed in Centiloids
por: Rowe, Christopher C., et al.
Publicado: (2017)

Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease
por: Lannfelt, Lars, et al.
Publicado: (2014)

Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease
por: Dansson, Hákon Valur, et al.
Publicado: (2021)

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
por: Palmqvist, Sebastian, et al.
Publicado: (2015)

A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study
por: Villemagne, Victor L., et al.
Publicado: (2017)

Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers
por: Sardar Sinha, Maitrayee, et al.
Publicado: (2018)

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
por: Bateman, Randall J., et al.
Publicado: (2022)

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
por: Hölttä, Mikko, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_3ut0i2fi7gni1hjknndimtq04g